306 related articles for article (PubMed ID: 24894095)
1. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
Takenaka T; Takenoyama M; Yamaguchi M; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Yoshida T; Shiraishi Y; Morodomi Y; Hirai F; Taguchi K; Shimokawa M; Seto T; Ichinose Y
Eur J Cardiothorac Surg; 2015 Mar; 47(3):550-5. PubMed ID: 24894095
[TBL] [Abstract][Full Text] [Related]
2. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
3. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
4. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
[TBL] [Abstract][Full Text] [Related]
5. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
6. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
7. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.
Okami J; Taniguchi K; Higashiyama M; Maeda J; Oda K; Orita N; Koizumi K; Kodama K; Kato K
Oncology; 2007; 72(3-4):234-42. PubMed ID: 18176089
[TBL] [Abstract][Full Text] [Related]
9. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.
Sun JM; Rampal S; Lee G; Lee J; Choi YL; Parasuraman B; Guallar E; Cho J; Shim YM
Lung Cancer; 2013 May; 80(2):191-6. PubMed ID: 23384673
[TBL] [Abstract][Full Text] [Related]
10. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW
Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153
[TBL] [Abstract][Full Text] [Related]
11. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
12. Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer.
Takenaka T; Inamasu E; Yoshida T; Toyokawa G; Nosaki K; Hirai F; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
Surg Today; 2016 Apr; 46(4):430-6. PubMed ID: 26070907
[TBL] [Abstract][Full Text] [Related]
13. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Li W; Ren S; Li J; Li A; Fan L; Li X; Zhao C; He Y; Gao G; Chen X; Li S; Shi J; Zhou C; Fei K; Schmid-Bindert G
Lung Cancer; 2014 Jun; 84(3):295-300. PubMed ID: 24685306
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Fukihara J; Watanabe N; Taniguchi H; Kondoh Y; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Hasegawa Y
Oncology; 2014; 86(2):86-93. PubMed ID: 24457318
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M
Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.
Kim HR; Lee JC; Kim YC; Kim KS; Oh IJ; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Ryu JS; Jang SH; Son JW; Lee JE; Kim SY; Kim HJ; Lee KY
Lung Cancer; 2014 Feb; 83(2):252-8. PubMed ID: 24309368
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery.
Ahn HK; Choi YL; Han JH; Ahn YC; Kim K; Kim J; Shim YM; Um SW; Kim H; Kwon OJ; Sun JM; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2013 Mar; 79(3):300-6. PubMed ID: 23261144
[TBL] [Abstract][Full Text] [Related]
20. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]